Benefits
Outperformed milk thistle (silymarin) head-to-head
In a 12-week double-blind placebo-controlled trial in 90 adults with elevated Fatty Liver Index, 4Liver at 300 mg/day produced greater reductions in liver enzymes (ALT, AST, ALP, GGT) than silymarin (milk thistle) at 320 mg/day. ALT reduction with 4Liver was approximately 22% vs placebo. GGT reduction approximately 17% vs baseline. First nutraceutical ingredient to outperform the long-standard silymarin in a direct head-to-head trial.
Fatty Liver Index (FLI) reduction
4Liver at 300 mg/day for 12 weeks significantly reduced Fatty Liver Index (FLI) in non-alcoholic adults with elevated baseline FLI. The FLI score is calculated from waist circumference, BMI, serum triglycerides, and GGT — a validated screening tool for non-alcoholic fatty liver disease (NAFLD) without imaging.
Liver enzyme normalization
Multiple liver enzymes (ALT, AST, ALP, GGT) reduced significantly with 4Liver supplementation vs placebo. Elevated liver enzymes are clinical markers of hepatic stress and injury. The broad enzyme normalization pattern suggests multi-pathway hepatoprotection rather than narrow single-mechanism activity.
Lipid profile improvement
4Liver supplementation improved cholesterol levels comparably to silymarin, and 4Liver additionally produced improvements in triglyceride levels not seen with silymarin alone. Lipid effects are mechanistically tied to liver function — the liver is the primary site of lipoprotein synthesis and cholesterol regulation.
Oxidative stress reduction
The 12-week trial documented reduction in oxidative stress markers with 4Liver supplementation. Oxidative stress is a central driver of hepatic injury in NAFLD and other liver conditions. Both component botanicals (Terminalia chebula and Sphaeranthus indicus) have documented antioxidant properties supporting this mechanism.
Quality of life improvements
The trial included Short-Form-36 (SF-36) quality-of-life assessment. 4Liver participants showed improvements in physical functioning, emotional functioning, and vitality — including ability to perform daily tasks (climbing stairs, walking, bending, bathing, dressing). Clinically meaningful patient-reported outcomes complement the biomarker improvements.
Ayurvedic precedent and modern positioning
Both Terminalia chebula and Sphaeranthus indicus have long traditional use in Ayurvedic medicine for liver and digestive support. Modern positioning addresses what Saanroo identifies as a gap in the liver health category — silymarin has been the standard for decades with limited innovation since. 4Liver represents the first novel modern alternative with comparable or superior clinical evidence.
Mechanism of action
Hepatoprotective antioxidant activity
Both Terminalia chebula and Sphaeranthus indicus contain polyphenolic compounds with documented antioxidant activity in hepatic tissue. Oxidative stress is a central driver of hepatic injury in NAFLD and other liver conditions — reducing it supports liver tissue function and recovery. Direct ROS scavenging and endogenous antioxidant enzyme upregulation both documented.
Anti-inflammatory effects on liver tissue
Both component herbs have documented anti-inflammatory effects spanning multiple pathways including NF-κB and pro-inflammatory cytokine modulation. Inflammation is the second major driver of NAFLD progression to NASH (non-alcoholic steatohepatitis). Anti-inflammatory effects on liver tissue support the broader hepatoprotective profile beyond pure antioxidant activity.
Lipid metabolism modulation
The clinical effects on cholesterol and triglycerides indicate modulation of hepatic lipid metabolism — including triglyceride synthesis, lipoprotein assembly, and bile acid recycling. The improvement in triglycerides (which silymarin alone did not produce in the head-to-head trial) suggests 4Liver has broader lipid effects than pure silymarin.
Adaptogenic effects
Saanroo positions 4Liver as an 'adaptogenic' liver support ingredient — supporting the liver's adaptation to physical, chemical, and biological stressors. Both component botanicals have traditional adaptogenic positioning in Ayurvedic medicine. The mechanism is less clearly characterized than antioxidant or anti-inflammatory pathways but is consistent with broader tissue-resilience effects.
Clinical trials
4Liver at 300 mg/day outperformed silymarin (milk thistle) at 320 mg/day on multiple liver enzyme markers: ALT reduction of approximately 22% vs placebo, GGT reduction of 17% vs baseline.
90 non-alcoholic overweight adults with elevated Fatty Liver Index (FLI). 12-week intervention.
4Liver at 300 mg/day outperformed silymarin (milk thistle) at 320 mg/day on multiple liver enzyme markers: ALT reduction of approximately 22% vs placebo, GGT reduction of 17% vs baseline. Fatty Liver Index reduced significantly. Both 4Liver and silymarin improved cholesterol; 4Liver additionally improved triglycerides. First nutraceutical to outperform silymarin head-to-head — important benchmark in the liver health category. SF-36 quality-of-life scores improved across physical functioning, emotional functioning, and vitality.
Beyond the 4Liver-specific clinical trial, each of the two component herbs has independent traditional use and modern preclinical evidence in liver health. Terminalia chebula (chebulic myrobalan) is one of the 'three myrobalans' in Ayurvedic medicine with extensive traditional use. Sphaeranthus indicus has both traditional hepatoprotective use and modern preclinical data.
Not applicable — preclinical and traditional-use evidence summary.
Both component herbs have documented hepatoprotective effects in preclinical models — antioxidant, anti-inflammatory, and direct hepatocyte protection mechanisms. The patent-pending 2:1 ratio (Terminalia: Sphaeranthus) appears to provide synergistic effects in the human trial beyond what either single botanical produces alone. Supports the rationale for the specific combination ratio rather than single-herb supplementation.